Want to see HK:1763 full AI Analyst Report?
1763 Stock Chart & Stats
HK$23.52
-HK$0.08(-0.76%)
At close: 4:00 PM EST
HK$23.52
-HK$0.08(-0.76%)
Day’s Range― - ―
52-Week RangeHK$13.06 - HK$25.00
Previous CloseN/A
Volume52.80K
Average Volume (3M)90.48K
Market Cap
HK$4.47B
Enterprise ValueHK$9.93K
Total Cash (Recent Filing)HK$2.59B
Total Debt (Recent Filing)HK$2.73B
Price to Earnings (P/E)11.5
Beta0.73
Next Earnings
Mar 31, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.59%
Share Statistics
EPS (TTM)1.00
Shares Outstanding79,968,800
10 Day Avg. Volume121,600
30 Day Avg. Volume90,480
Financial Highlights & Ratios
PEG Ratio-0.85
Price to Book (P/B)1.11
Price to Sales (P/S)0.83
P/FCF Ratio-119.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.76
Revenue Forecast (FY)HK$9.04B
Bulls Say, Bears Say
Bulls Say
Resilient Operating MarginsThe roughly 50% gross margin and double-digit EBIT and EBITDA margins show that the irradiation and sterilization operation retains meaningful operating profitability. This resilience provides an earnings base for continued investment and helps cushion the effect of weaker demand over the next several quarters.
Adequate CapitalizationEquity of about 5.23B supports a 15.72B asset base, while 2025 debt-to-equity of roughly 0.52 indicates moderate leverage in absolute terms. This capitalization provides a financial foundation for ongoing operations and supports the company’s ability to serve multiple irradiation markets.
Improved Operating Cash FlowOperating cash flow improved substantially in 2025, reaching approximately 538M after much lower levels in the prior two years. If sustained, stronger internal cash generation could improve funding flexibility and help support operations without relying as heavily on external financing.
Bears Say
Revenue ContractionThe 2025 revenue decline marks a meaningful reversal from the company’s earlier growth pattern and signals weaker demand or activity across its irradiation-related markets. Continued contraction would reduce operating leverage, constrain reinvestment capacity, and make sustained profit growth more difficult.
Thin And Compressed Net MarginA net margin of approximately 4.6% leaves relatively little bottom-line buffer after operating costs and other charges. Its decline from prior levels means revenue weakness could translate disproportionately into earnings pressure, limiting the company’s ability to absorb setbacks while preserving returns.
Volatile Free Cash FlowDespite positive free cash flow in 2025, the large multi-year swings indicate inconsistent cash conversion and reduce confidence in internally generated funding. This volatility can complicate capital planning, increase reliance on financing during investment periods, and limit flexibility if operating conditions weaken.
China Isotope & Radiation Corp. News
1763 FAQ
What was China Isotope & Radiation Corp.’s price range in the past 12 months?
China Isotope & Radiation Corp. lowest stock price was HK$13.06 and its highest was HK$25.00 in the past 12 months.
What is China Isotope & Radiation Corp.’s market cap?
China Isotope & Radiation Corp.’s market cap is HK$4.47B.
When is China Isotope & Radiation Corp.’s upcoming earnings report date?
China Isotope & Radiation Corp.’s upcoming earnings report date is Mar 31, 2027 which is in 201 days.
How were China Isotope & Radiation Corp.’s earnings last quarter?
China Isotope & Radiation Corp. released its earnings results on Aug 28, 2026. The company reported HK$0.58 earnings per share for the quarter.
Is China Isotope & Radiation Corp. overvalued?
According to Wall Street analysts China Isotope & Radiation Corp.’s price is currently Overvalued.
Does China Isotope & Radiation Corp. pay dividends?
China Isotope & Radiation Corp. pays a Semiannually dividend of HK$0.116 which represents an annual dividend yield of 2.59%. See more information on China Isotope & Radiation Corp. dividends here
What is China Isotope & Radiation Corp.’s EPS estimate?
China Isotope & Radiation Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does China Isotope & Radiation Corp. have?
China Isotope & Radiation Corp. has 79,968,800 shares outstanding.
What happened to China Isotope & Radiation Corp.’s price movement after its last earnings report?
China Isotope & Radiation Corp. reported an EPS of HK$0.58 in its last earnings report. Following the earnings report the stock price went down -0.118%.
Which hedge fund is a major shareholder of China Isotope & Radiation Corp.?
Currently, no hedge funds are holding shares in HK:1763
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
China Isotope & Radiation Corp. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.15%
12-Months-Change
Fundamentals
Return on Equity
2.59%
Trailing 12-Months
Asset Growth
11.39%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
China Isotope & Radiation Corp.
China Isotope & Radiation Corporation is dedicated to the development, production, and distribution of diagnostic and therapeutic radiopharmaceuticals, as well as radioactive source products for both medical and industrial applications throughout China. The company's operations are divided into five principal areas. Its Pharmaceuticals division focuses on creating and marketing imaging diagnostic and therapeutic radiopharmaceuticals, UBT kits and analyzers, and in vitro immunoassay diagnostic reagents and kits. The Radioactive Source Products segment furnishes medical and industrial radioactive sources, along with associated technical support services. The Irradiation segment offers sterilization services for products such as medical devices, food, traditional Chinese medicine, and cosmetics, in addition to providing engineering, procurement, and construction (EPC) services for gamma ray irradiation facilities. The Radiation Therapy Equipment and Related Services segment handles the sale of radiation therapy equipment and its corresponding maintenance. Finally, the Independent Clinical Medical and Laboratory Services, and Other Business segment delivers independent clinical laboratory services to hospitals and other medical institutions, covering a range of conditions including hepatitis, endocrine disorders, bone metabolism issues, cardiovascular diseases, and diabetes. Founded in 1983, the company's main office is located in Beijing, China, and it operates as a subsidiary of China National Nuclear Corporation.
Technical Analysis
MicroPort Scientific
―
LifeTech Scientific Corporation
―
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H
―
MicroPort CardioFlow Medtech Corp.
―
MicroPort NeuroTech Limited
―